ClinicalTrials.gg
RecruitingNCT05768932Updated Jun 15, 2026

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of BAL0891 and Tislelizumab in Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer and Gastric Cancer, sponsored by SillaJen, Inc.. Recruiting at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Primary conditionnone(registry's first term: Triple Negative Breast Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Triple Negative Breast Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by SillaJen, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
260
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia. An adaptive model-based design will be used to guide the dose escalation. Subject assignment to Substudy 1, 2, 3 and 4 will be finalized following approval from the investigator and sponsor.

The dose-expansion stage will be conducted with the RP2D to further evaluate the preliminary anti-tumor activity, safety, and tolerability in metastatic TNBC and GC.

Read the detailed description

Substudy 1 (monotherapy dose-escalation cohorts) This study will be initiated with enrollment into Substudy 1 and will estimate the safety, tolerability, PK, and PD of increasing doses of BAL0891 in patients with advanced solid tumors. The starting dose will be 5 mg based on the GLP (Good Laboratory Practice) toxicology studies. Dose escalation will comprise a dose range from a dose of 5 mg up to a maximum absolute dose of 480 mg, with eight nominal dose levels (DLs) of 5 / 10 / 20 / 40 / 80 / 160 / 320 / 480 mg. Intra-patient dose escalations are only allowed for patients enrolled in single-patient DL Cohorts 1.1, 1.2, and 1.3. From DL Cohort 1.4 onwards, the projected maximum dose-escalation factor will be two-fold; if the DL cohort investigates an increased dose, dosing of the patients within the cohort must be separated by at least 7 days. For cohorts in which doses are not increased (including backfill enrollment), patients may be enrolled concurrently.

BAL0891 will be administered intravenously (IV) on Day (D) 1 and D8 every 3 weeks (Q3W); for the schedule of assessments of Regimen A. Alternative 21-day or 28-day dosing regimens may be investigated; for the schedule of assessments of Regimens B-D.

Substudies 2 and 3 (dose-escalation cohorts for combination regimens) Enrollment into Substudies 2 and 3 may commence as early as first signs of expected target toxicity and/or efficacy with Regimen A (or an alternative monotherapy regimen) have been observed, or alternatively, once the MTD of BAL0891 monotherapy has been assessed. Patients enrolled into Substudies 2 and 3 will be treated with increasing doses of BAL0891 in combination with tislelizumab or paclitaxel, respectively, and dose escalation of both BAL0891 and tislelizumab/paclitaxel if required will use the same cumulative BLRM-EWOC model as Substudy 1. The starting dose of BAL0891 in combination with tislelizumab or paclitaxel will be a safe DL determined in Substudy 1 but not higher than approximately half the MTD. Backfill enrollment of up to a total of 30 additional patients for both substudies (who may be enrolled concurrently) may be used to better estimate the RP2D for each combination if required.

Substudy 4 (dose escalation cohort for monotherapy in r/r AML) Substudy 4 will evaluate BAL0891 monotherapy in patients with relapsed/refractory AML (r/r AML) using the same BLRM-EWOC model and study design described for Substudy 1. BAL0891 will be administered intravenously on Day 1 and Day 8 every three weeks (Regimen A; see Table 13 for schedule of assessments). Dose exploration will proceed until the highest planned dose level (DL) is determined to be safe and tolerable, or the MTD/RP2D is identified.

Each DL cohort will enroll three patients, with DLT observation required before advancing to the next DL. From DL2 onward, the projected maximum dose-escalation factor will be two-fold, with concurrent enrollment allowed for cohorts without dose increases. Backfill enrollment may be conducted to refine the RP2D and further characterize safety, efficacy and PD.

Part 2 : Dose expansion The commencement of the dose expansion stage will follow the determination of the RP2D achieved during the dose-escalation phase. This stage will consist of four cohorts, each comprising 24 patients who have previously undergone at least one systemic regimen for advanced or metastatic disease. Specifically, two cohorts will be allocated for TNBC, investigating BAL0891 both as a monotherapy and in combination with Paclitaxel. Additionally, two cohorts will be designated for GC, investigating the outcomes of BAL0891 as a monotherapy and in combination with Paclitaxel.

02

Conditions studied

  • Advanced Solid Tumor
  • TNBC - Triple-Negative Breast Cancer
  • Gastric Cancer
  • Leukemia Acute Myeloid Leukemia (AML)

Keywords

  • carcinoma
  • paclitaxel
  • BAL0891
  • tislelizumab
03

In context

Lead sponsor

SillaJen, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

1.1. Inclusion criteria: Substudy 1, 2, 3 and Dose expansion Each patient must meet all the following inclusion criteria.

  1. signed by the patient prior to any study-related procedure indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate in the study.
  2. Male or female aged ≥18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.
  3. Patients with incurable advanced/ solid tumor disease to or intolerant of existing therapy known to provide clinical benefit for their condition.

    Note: Patients with non-CNS tumors participating during dose escalation may have inactive , defined as 4 weeks after either brain metastasis resection or radiation, and a) all residual neurological symptoms resolved to grade ≤ 2; b) on stable doses of dexamethasone, if applicable; and c) follow-up imaging shows no new lesions appearing.

  4. Patients enrolled in Dose Expansion only

    • TNBC cohorts i. Must have confirmed breast adenocarcinoma that is unresectable, loco-regional, or metastatic.

    ii. Must have source data documented pathologically confirmed triple negative breast cancer, defined as both of the following.

    1. Estrogen receptor (ER) and progesterone receptor (PgR) negative: \<1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls)
    2. Human epidermal growth factor receptor 2 () negative as per American Society of Clinical Oncology/College of American Pathologists guidelines

      • IHC 0 or 1 fluorescence in situ hybridization (FISH) negative (or equivalent negative test)
      • Patients with IHC 2 must have a negative by FISH (or equivalent negative test) iii. Patients with a history of different breast cancer phenotypes (i.e., ER/PgR/HER2 Positive) must obtain pathological confirmation of triple-negative disease in at least one of the current sites of metastasis.

    iv. Must have progression on or after therapy containing anthracycline and/or a taxane. Subjects must have received anthracycline and/or a taxane based regimen or other chemotherapy / targeted therapy regimen if anthracycline or taxane was or another available approved targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit.

    • GC cohort i. Must have a histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.

    ii. Must have progression on or after therapy containing platinum/fluoropyrimidine. Subjects must have received platinum-based chemotherapy or other chemotherapy regimen if platinum-based chemotherapy was contraindicated or another available approved targeted agent unless the targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit.

    iii. Documentation of HER2/neu status. Patients who are HER2/neu-positive must be treated with a HER2/neu inhibitor, and subjects should have progressed on or be intolerant to the targeted therapy or subjects must have received other chemotherapy regimen if HER2/neu inhibitor was contraindicated or another available approved targeted agent unless the targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit.

    iv. Subjects must/should have received no more than 3 for the advanced disease (if a subject progressed within 6 months of completing therapy, this would count as a prior line of therapy).

  5. For patients enrolled in Substudy 3 or cohort 3 and 4, if a taxane (i.e., paclitaxel or docetaxel) was administered as part of the previous regimen, PD must have occurred > 12 months from the end of the previous treatment. (Patients who received a taxane in previous treatments without reaching PD may enroll without the 12-month waiting period.)
  6. Patients enrolled in Dose Expansion only, patient must have undergone a minimum of 1 prior systemic regimen for advanced or metastatic disease. (Korea only, patients must have received the second line standard of care treatment as per the regulations of the respective country. Patients who are unsuitable to receive the standard of care second line treatment will be eligible for enrollment)
  7. performance status (ECOG PS) 0or-1
  8. For patients enrolled from DL1.4 of Substudy 1 onwards and for all patients in Substudies 2 and 3 and all four dose expansion cohorts, measurable tumor disease per 1.1 criteria (RECIST 1.1), i.e., a minimum of one target lesion.
  9. Adequate organ functions as indicated by the following Screening visit local laboratory values:

    1. ≥ 9 g/dL (criterion must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 4 weeks)
    2. ≥ 2.0 × 109/L; criterion must be met without growth factor (e.g., G-CSF, GM CSF, etc.) administration within the last 2 weeks
    3. ≥ 100 × 109/L
    4. Total ≤ 1.5 ×
    5. (AST) and alanine aminotransferase (ALT) baseline levels ≤ 1.5 × ULN, with the option for AST/ALT ≤ 3.0 × ULN, or ≤ 5.0 × ULN for patients with liver metastasis, upon accumulating evidence for the absence of liver toxicity in biologically active DLs
    6. Albumin ≥ 2.8 g/dL
    7. CLCR ≥ 50 mL/min (as calculated by the formula), or ≥ 50 mL/min/1.73 m² (MDRD equation or CKD-EPI equation)
    8. For women of , negative serum human chorionic gonadotropin (hCG)
  10. Men/women of child-producing/bearing potential must agree to: avoid impregnating a partner or becoming pregnant, respectively, during the study, and for at least 6 months after the last dose of either drug, and comply with the requirements.

1.2. Inclusion criteria: Substudy 4 Each patient must meet all the following inclusion criteria.

  1. Informed consent signed by the patient prior to any study-related procedure indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate in the study.
  2. Male or female aged ≥18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.
  3. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
  4. Estimated of at least 8 weeks
  5. AML either de novo or secondary as any subtype diagnosed according to the WHO 2022 classification system [except acute promyelocytic leukemia (APL)] who either:

    Relapse/refractory (R/R) acute myeloid leukemia (AML) defined as those who have also failed or are not appropriate for any approved standard-of-care (SOC) therapies, or hematopoietic stem cell transplant () with reappearance of ≥ 5% blasts in the bone marrow.

  6. Relapsed AML is defined as having 5% or more leukemic blasts in the bone marrow, reappearance of leukemic blasts in peripheral blood (in at least two peripheral blood samples taken at least one week apart), or the development of new extramedullary disease.
  7. WBC, peripheral blood leukocyte count≤ 25,000/µL and blast count ≤ 25,000/µL prior to initiation of therapy

    1. Hydroxyurea is allowed during screening and prior to day 1 of study treatment to keep the blast count ≤25,000/µL; hydroxyurea is to be ceased 24 hours prior to study therapy.
    2. Hydroxyurea may be used for up to 28 days in the initial treatment cycle if needed, to keep the white blood cell (WBC) count ≤25,000/µL. However, no other anti-leukemic treatments, apart from the study drug, are allowed during this period.
    3. Leukapheresis is allowed to maintain blast count ≤25,000/µL
  8. Adequate organ functions as indicated by the following Screening visit local laboratory values:

    1. CLCR ≥ 60 mL/min (as calculated by the Cockcroft-Gault formula), or eGFR ≥ 60 mL/min/1.73 m² (MDRD equation or CKD-EPI equation)
    2. Total bilirubin ≤ 1.5 × ULN (unless considered due to leukemic organ involvement), or, Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
    3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) baseline levels ≤ 3.0 × ULN
    4. Albumin ≥ 2.5 g/dL
    5. (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
    6. Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  9. Men/women of child-producing/bearing potential must agree to: avoid impregnating a partner or becoming pregnant, respectively, during the study, and for at least 6 months after the last dose of either investigational drug, and comply with the contraception requirements.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Part 1: Substudy 1, Dose-escalation substudy of BAL0891 monotherapy

    Increasing doses of BAL0891 will be administered IV on D1 and D8 Q3W (Regimen A). BAL0891 will be investigated in a dose range of 5-480 mg with Regimen A. Optionally, and based on cumulative safety, PK, and PD data, BAL0891 may be administered on D1 Q3W (Regimen B), D1 and D15 Q4W (Regimen C), or on D1, D8, and D15 Q4W (Regimen D).

    Drug: BAL0891

  • Experimental
    Part 1: Substudy 2, Dose-escalation substudy of BAL0891 in combination with tislelizumab

    Increasing doses of BAL0891 will be administrated IV on D1 and D15 with tislelizumab administration on D8 Q3W. The starting dose of BAL0891 for combination will be at approximately 50% of the BAL0891 monotherapy MTD determined in Substudy 1 and tislelizumab dose will be 200mg IV.

    Drug: BAL0891 · Combination Product: Tislelizumab

  • Experimental
    Part 1: Substudy 3, Dose-escalation substudy of BAL0891 in combination with paclitaxel

    Paclitaxel will be dosed at 70 mg/m2 on D1, D8, and D15 Q4W, with an option to use 80 mg/m2 (either instead of, or after exploring, 70 mg/m2) if the cumulative data collected at that time support a higher dose of paclitaxel.

    Drug: BAL0891 · Combination Product: Paclitaxel

  • Experimental
    Part 2 : Dose expansion, cohorts 1 TNBC (BAL0891 monotherapy)

    BAL0891 will be administered intravenously on D1 and D8, Q3W for cohorts 1. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 1 will utilize the RP2D established in substudy 1 of the dose escalation phase.

    Drug: BAL0891

  • Experimental
    Part 2 : Dose expansion, cohorts 2 GC (BAL0891 monotherapy)

    BAL0891 will be administered intravenously on D1 and D8, Q3W for cohorts 2. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 2 will utilize the RP2D established in substudy 1 of the dose escalation phase.

    Drug: BAL0891

  • Experimental
    Part 2 : Dose expansion, cohorts 3 TNBC (BAL0891 + Paclitaxel)

    BAL0891 will be administered intravenously on D1 and D15, Q4W for cohorts 3 . The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 3 will utilize the RP2D established in substudy 3 of the dose escalation phase.

    Drug: BAL0891 · Combination Product: Paclitaxel

  • Experimental
    Part 2 : Dose expansion, cohorts 4 GC (BAL0891 + Paclitaxel)

    BAL0891 will be administered intravenously on D1 and D15, Q4W for cohorts 4. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 4 will utilize the RP2D established in substudy 3 of the dose escalation phase.

    Drug: BAL0891 · Combination Product: Paclitaxel

  • Experimental
    Part 1: Substudy 4, Dose-escalation substudy of BAL0891 monotherapy in r/r AML

    BAL0891 will be administered intravenously on Day 1 and Day 8 every three weeks (Regimen A). Dose exploration will proceed until the highest planned dose level (DL) is determined to be safe and tolerable, or the MTD/RP2D is identified.

    Drug: BAL0891

Interventions

  • DrugBAL0891

    BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)

    Also known as: TTK-CS-101

  • Combination productTislelizumab

    Tislelizumab a humanized IgG4 anti-PD-1 monoclonal antibody

  • Combination productPaclitaxel

    Paclitaxel is a natural product with antitumor activity

    Also known as: Taxol

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Safety is collected through summaries of AE(Adverse Event)s, safety laboratory evaluations, PK evaluations, physical examinations, vital signs, and ECGs using CTCAE v5.0.

    Time frame: After first dose, up to 2 years

  2. Part 1: Number of Participants With the DLT (Dose-limiting toxicity)s as a Measure of maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)

    DLTs are collected through BLRM-EWOC.

    Time frame: After first dose and within 7 days of End of Treatment, up to 2 years

  3. Part 2: Overall response rate (ORR) for all subjects

    The proportion of patients with confirmed complete response (CR) or partial response (PR) by RECIST 1.1/iRECIST (substudy 2 only) during the dose expansion phase.

    Time frame: Every 3 months (±14 days) after first dose, up to 2 years

Secondary outcomes

  1. Part 1: Pharmacokinetics (PK) parameters for all subjects

    The area under the plasma concentration-time curve (AUC) by PK Sampling

    Time frame: Within 7 days of End of Treatment, up to 2 years

  2. Part 1: Absolute neutrophil count (ANC) for all subjects

    Duration of neutropenia by PD Sampling

    Time frame: Within 7 days of End of Treatment, up to 2 years

  3. Part 1, 2: Overall response rate (ORR) for all subjects

    The proportion of patients with confirmed complete response (CR) or partial response (PR) by RECIST 1.1

    Time frame: Every 3 months (±14 days) after first dose, up to 2 years

  4. Part 1, 2: Disease control rate (DCR) for all subjects

    The proportion of patients with confirmed CR, PR or stable disease (SD) by RECIST 1.1

    Time frame: Within 7 days of End of Treatment, up to 2 years

  5. Part 1, 2: Progression-free survival (PFS) for all subjects

    Measured from patient enrollment to disease progression date

    Time frame: Within 7 days of End of Treatment, up to 2 years

  6. Part 1, 2: Overall survival (OS) for all subjects

    Measured from from patient enrollment to time of death

    Time frame: Within 7 days of End of Treatment, up to 2 years

  7. Part 2: Safety evaluations for all subjects

    Safety evaluations is focusing on key clinical evlauations such treatment-emergent adverse events (TEAE) using CTCAE v5.0.

    Time frame: After first dose, up to 2 years

  8. Part 1: Efficacy Endpoints CR + CRh Rate (Substudy 4)

    Proportion of patients achieving Complete Remission (CR) or CR with partial hematologic recovery (CRh) per European LeukemiaNet (ELN) 2022 guidelines.

    Time frame: Up to 2 years

  9. Part 1: Efficacy Endpoints Duration of Remission (DoR) (Substudy 4)

    Time from first documented CR/CRh until relapse or death.

    Time frame: Up to 2 years

  10. Part 1: Efficacy Endpoints Transfusion Independence (TI) (Substudy 4)

    Proportion of patients achieving red blood cell (RBC) and platelet transfusion independence for ≥56 consecutive days.

    Time frame: Up to 2 years

  11. Part 1: Efficacy Endpoints CR/CRh without Measurable Residual Disease (MRD) (Substudy 4)

    Proportion of patients achieving CR/CRh and MRD negativity.

    Time frame: Up to 2 years

  12. Part 1: Efficacy Endpoints Composite Complete Remission (CRc) Rate (Substudy 4)

    Proportion of patients achieving CR, CRh, or CR with incomplete hematologic recovery (CRi).

    Time frame: Up to 2 years

  13. Part 1: Efficacy Endpoints Overall Response Rate (ORR) (Substudy 4)

    Proportion of patients achieving CR, CRh, CRi, or Partial Remission (PR).

    Time frame: Up to 2 years

  14. Part 1: Efficacy Endpoints Overall Survival (OS) (Substudy 4)

    Time from first dose of BAL0891 to death from any cause.

    Time frame: Up to 2 years

  15. Part 1: Efficacy Endpoints Event-Free Survival (EFS) (Substudy 4)

    Time from first dose of BAL0891 to disease progression, relapse, or death.

    Time frame: Up to 2 years

  16. Part 1: Efficacy Endpoints Time to Response (TTR) (Substudy 4)

    Time from first dose of BAL0891 to first documented response.

    Time frame: Up to 2 years

  17. Part 1: QTcF Interval Analysis

    Analysis of QTcF interval data collected during BAL0891 monotherapy and the relationship between BAL0891 exposure and QTcF interval prolongation.

    Time frame: From first dose to 30 days post last dose

07

Study locations

15 of 17 sites recruiting
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
    Recruiting
    • Yale New Haven Hospital · Contact
  • University of Miami Health System
    Coral Gables, Florida 33146, United States
    Recruiting
    • University of Miami Health System · Contact
  • Winship Cancer Institute / Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Winship Cancer Institute / Emory University · Contact
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • University of Michigan · Contact
  • New York Medicine-New York-Presbyterian Hospital
    New York, New York 10021, United States
    Recruiting
    • New York Medicine-New York-Presbyterian Hospital · Contact
  • Montefiore Medical Center - Montefiore Hospital
    New York, New York 10467, United States
    Recruiting
    • Montefiore Medical Center - Montefiore Hospital · Contact
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
    Recruiting
    • Montefiore Medical Center · Contact
  • OHSU Knight Cancer Institute
    Portland, Oregon 97239, United States
    Completed

    Not enrolling at this site.

  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
    Completed

    Not enrolling at this site.

  • Baylor University Medical Center
    Dallas, Texas 75246, United States
    Recruiting
    • Baylor University Medical Center · Contact
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • The University of Texas MD Anderson Cancer Center · Contact
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, South Korea
    Recruiting
    • The Catholic University of Korea, Seoul St. Mary's Hospital · Contact
  • Asan Medical Center
    Seoul, South Korea
    Recruiting
    • Asan Medical Center · Contact
  • Korean University Anam Hospital
    Seoul, South Korea
    Recruiting
    • Korean University Anam Hospital · Contact
  • Samsung Medical Center
    Seoul, South Korea
    Recruiting
    • Samsung Medical Center · Contact
  • Seoul National University Hospital
    Seoul, South Korea
    Recruiting
    • Seoul National University Hospital · Contact
  • Severance Hospital, Yonsei University Health System
    Seoul, South Korea
    Recruiting
    • Severance Hospital, Yonsei University Health System · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2023
First posted
Mar 15, 2023
StartActual
Dec 14, 2022
Primary completionEst.
Dec 24, 2026
CompletionEst.
Dec 24, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05768932
Lead sponsor
SillaJen, Inc.
Responsible party
Sponsor
First posted
Mar 15, 2023
Start date
Dec 14, 2022
Primary completion
Dec 24, 2026 (estimated)
Completion
Dec 24, 2026 (estimated)
Last update
Jun 15, 2026

Study contacts

SillaJen Inc.
Contact
patient_inquiry@sillajen.com
02-368-2600
SillaJen Inc.
study director · SillaJen, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion